Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ricard Cervera

Showing results (391-400 of 412) with videos related to

Pageof 42
Sort By:
Annals of the Rheumatic Diseases|November 20, 2025
Clinical and biologic predictors of thrombosis in persistently antiphospholipid antibody-positive patients: Prospective analysis of the International APS ACTION Clinical Database and Repository ('Registry')Jonathan Thaler, Michael Parides, Danieli Castro Oliveira de Andrade, et al.
Advances in Rheumatology (London, England)|April 17, 2026
Do ethnoracial differences exist among antiphospholipid antibody-positive patients with no other systemic autoimmune diseases: results from the APS ACTION registryElena Gkrouzman, Alicia Matijasevich, Carolina Bonilla Richero, et al.
Autoimmunity Reviews|December 16, 2020
The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' ConsensusRoberto Giacomelli, Antonella Afeltra, Elena Bartoloni, et al.
Clinical and Experimental Rheumatology|July 30, 2025
Antiphospholipid antibody-related clinical manifestations during childhood versus adulthood: descriptive results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repositoryJheel Pandya Bhatt, Marissa Dale, Danieli Castro Oliveira de Andrade, et al.
Annals of the Rheumatic Diseases|October 12, 2023
EULAR recommendations for the management of systemic lupus erythematosus: 2023 updateAntonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, et al.
The Lancet. Rheumatology|May 26, 2025
ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestationsLaurent Arnaud, Guillermo Ruiz-Irastorza, Cynthia Aranow, et al.
Therapeutic Advances in Musculoskeletal Disease|July 18, 2025
Impact of conflicting information on the use of antirheumatic drugs in pregnancy and breastfeeding: perspectives of healthcare providers from the global PRAISE surveyKaren Schreiber, Christine Graversgaard, Ioannis Parodis, et al.
Autoimmunity Reviews|July 15, 2017
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease managementRoberto Giacomelli, Antonella Afeltra, Alessia Alunno, et al.
Clinical and Experimental Rheumatology|March 14, 2023
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody productsRosaria Talarico, Giuseppe Alvise Ramirez, Sofia C Barreira, et al.
Annals of the Rheumatic Diseases|November 26, 2016
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)Ronald van Vollenhoven, Alexandre Voskuyl, George Bertsias, et al.
Pageof 42

Showing results (391-400 of 412) with videos related to

Sort By:
Pageof 42
Annals of the Rheumatic Diseases|November 20, 2025
Clinical and biologic predictors of thrombosis in persistently antiphospholipid antibody-positive patients: Prospective analysis of the International APS ACTION Clinical Database and Repository ('Registry')Jonathan Thaler, Michael Parides, Danieli Castro Oliveira de Andrade, et al.
Advances in Rheumatology (London, England)|April 17, 2026
Do ethnoracial differences exist among antiphospholipid antibody-positive patients with no other systemic autoimmune diseases: results from the APS ACTION registryElena Gkrouzman, Alicia Matijasevich, Carolina Bonilla Richero, et al.
Autoimmunity Reviews|December 16, 2020
The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' ConsensusRoberto Giacomelli, Antonella Afeltra, Elena Bartoloni, et al.
Clinical and Experimental Rheumatology|July 30, 2025
Antiphospholipid antibody-related clinical manifestations during childhood versus adulthood: descriptive results from the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) clinical database and repositoryJheel Pandya Bhatt, Marissa Dale, Danieli Castro Oliveira de Andrade, et al.
Annals of the Rheumatic Diseases|October 12, 2023
EULAR recommendations for the management of systemic lupus erythematosus: 2023 updateAntonis Fanouriakis, Myrto Kostopoulou, Jeanette Andersen, et al.
The Lancet. Rheumatology|May 26, 2025
ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestationsLaurent Arnaud, Guillermo Ruiz-Irastorza, Cynthia Aranow, et al.
Therapeutic Advances in Musculoskeletal Disease|July 18, 2025
Impact of conflicting information on the use of antirheumatic drugs in pregnancy and breastfeeding: perspectives of healthcare providers from the global PRAISE surveyKaren Schreiber, Christine Graversgaard, Ioannis Parodis, et al.
Autoimmunity Reviews|July 15, 2017
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease managementRoberto Giacomelli, Antonella Afeltra, Alessia Alunno, et al.
Clinical and Experimental Rheumatology|March 14, 2023
ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody productsRosaria Talarico, Giuseppe Alvise Ramirez, Sofia C Barreira, et al.
Annals of the Rheumatic Diseases|November 26, 2016
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)Ronald van Vollenhoven, Alexandre Voskuyl, George Bertsias, et al.
Pageof 42